"A pivotal year ahead for this ASX shareThe third ethical ASX share Gracey has an optimistic outlook on is biotech company Immutep Ltd (ASX: IMM). His fund has a holding in the immunotherapy drug developer.According to Gracey, "Immutep should have a pivotal year in 2024. We expect to see continued strong clinical data in lung cancer as well as head and neck cancer treatments."He added:Immutep is the number two globally in clinical development of a new class of immunotherapy called LAG3. To date this has shown to enhance the clinical efficacy of cancer treatments, with few safety issues when combined with the global leading immunotherapy Keytruda, which is owned by pharmaceutical giant Merck.This ethical ASX share has gained 21% over the past 12 months." Motely Fool
Media, page-602
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.5¢ | 41.0¢ | $882.4K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54134 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 16576 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
42.0¢ |
Change
0.010 ( 1.40 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 42.3¢ | 41.0¢ | 441363 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| IMM (ASX) Chart |
